CD11c⁺ and IRF8⁺ cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–9. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellisé M, Esteban L, Kaminski MF, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019;68(10):1820–1826. doi:10.1136/gutjnl-2018-317592.
   PubMed Web of Science ®Google Scholar
• Wan T, Zhang XF, Liang C, Liao CW, Li JY, Zhou YM. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies. Ann Surg Oncol. 2019;26(5):1412–1420. doi:10.1245/s10434-018-07147-0.
   PubMed Web of Science ®Google Scholar
• Jalilian M, Davis S, Mohebbi M, Sugamaran B, Porter IW, Bell S, Warrier SK, Wale R. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome. J Gastrointest Oncol. 2016;7(4):603–608. doi:10.21037/jgo.2016.05.03.
   PubMed Web of Science ®Google Scholar
• Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–513. doi:10.1016/S2468-1253(17)30074-2.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen Y-S, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–404. doi:10.1038/nature10755.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 2011;6(1):49. doi:10.1186/1748-717X-6-49.
   PubMedGoogle Scholar
• El Sissy C, Kirilovsky A, Van den Eynde M, Musina AM, Anitei MG, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26(19):5198–5207.
   PubMed Web of Science ®Google Scholar
• Sendoya JM, Iseas S, Coraglio M, Golubicki M, Robbio J, Salanova R, Kujaruk M, Mikolaitis V, Rizzolo M, Ruiz G, et al. Pre-existing tumoral B cell infiltration and impaired genome maintenance correlate with response to chemoradiotherapy in locally advanced rectal cancer. Cancers. 2020;12(8):2227. doi:10.3390/cancers12082227.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tian W, Su L, Li P, Gong X, Shi L, Zhang Q, Zhao B, Zhao H. Tumor-infiltrating cytotoxic T cells and tumor-associated macrophages correlate with the outcomes of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Front Oncol. 2021;11:743540. doi:10.3389/fonc.2021.743540.
   PubMed Web of Science ®Google Scholar
• Cancer AJCo. AJCC Cancer Staging Manual. 6 ed. F. L. Greene DLP, I. D. Fleming, A. G. Fritz, C. M. Balch, D. G. Haller, & M. Morrow, editor. New York, NY: Springer; 2002.
   Google Scholar
• Cancer AJCo. AJCC Cancer Staging Handbook. 7 ed. Stephen B. Edge DRB, Carolyn C. Compton, April G. Fritz, Frederick L. Greene, Andrew Trotti, editors. New York, NY: Springer; 2010.
   Google Scholar
• Ashhurst TM, Marsh-Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, Smith AL, King NJC. Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. Cytometry A. 2022;101(3):237–253. doi:10.1002/cyto.a.24350.
   PubMed Web of Science ®Google Scholar
• Mair F, Liechti T. Comprehensive phenotyping of human dendritic cells and monocytes. Cytometry A. 2021;99(3):231–242. doi:10.1002/cyto.a.24269.
   PubMed Web of Science ®Google Scholar
• Plesca I, Müller L, Böttcher JP, Medyouf H, Wehner R, Schmitz M. Tumor-associated human dendritic cell subsets: phenotype, functional orientation, and clinical relevance. Eur J Immunol. 2022;52(11):1750–1758. doi:10.1002/eji.202149487.
   PubMed Web of Science ®Google Scholar
• Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003;52(7):423–428. doi:10.1007/s00262-003-0388-5.
   PubMed Web of Science ®Google Scholar
• Miyakita H, Sadahiro S, Suzuki T, Chan LF, Ogimi T, Okada K, Yamamoto S, Kajiwara H. Tumor-infiltrating lymphocytes in biopsy specimens obtained 7 days after starting chemoradiotherapy for rectal cancer are predictors of the response to chemoradiotherapy. Oncology. 2020;98(12):869–875. doi:10.1159/000508922.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Akiyoshi T, Yamamoto N, Mukai T, Hiyoshi Y, Yamaguchi T, Nagasaki T, Fukunaga Y, Hirota T, Noda T, et al. Tumor-infiltrating PD-1+ immune cell density is associated with response to neoadjuvant chemoradiotherapy in rectal cancer. Clin Colorectal Cancer. 2022;21(1):e1–e11. doi:10.1016/j.clcc.2022.01.004.
   PubMed Web of Science ®Google Scholar
• Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, Kajiwara Y, Kobayashi H, Ishiguro M, Yamamoto J. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2014;21(Suppl S3):S414–421. doi:10.1245/s10434-014-3584-y.
   PubMedGoogle Scholar
• Park IJ, An S, Kim SY, Lim HM, Hong SM, Kim MJ, Kim YJ, Yu CS. Prediction of radio-responsiveness with immune-profiling in patients with rectal cancer. Oncotarget. 2017;8(45):79793–79802. doi:10.18632/oncotarget.19558.
   PubMedGoogle Scholar
• McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 2017;8(12):19803–19813. doi:10.18632/oncotarget.15048.
   PubMedGoogle Scholar
• McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, Platell CF. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer. 2015;113(12):1677–1686. doi:10.1038/bjc.2015.427.
   PubMed Web of Science ®Google Scholar
• Chatila WK, Kim JK, Walch H, Marco MR, Chen CT, Wu F, Omer DM, Khalil DN, Ganesh K, Qu X, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28(8):1646–1655. doi:10.1038/s41591-022-01930-z.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007;5(1):62. doi:10.1186/1479-5876-5-62.
   PubMedGoogle Scholar
• Heeran AB, Dunne MR, Morrissey ME, Buckley CE, Clarke N, Cannon A, Donlon NE, Nugent TS, Durand M, Dunne C, et al. The protein secretome is altered in rectal cancer tissue compared to normal rectal tissue, and alterations in the secretome induce enhanced innate immune responses. Cancers. 2021;13(3):571. doi:10.3390/cancers13030571.
   PubMed Web of Science ®Google Scholar
• Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011;32(11):1660–1667. doi:10.1093/carcin/bgr189.
   PubMed Web of Science ®Google Scholar
• Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, et al. Neoadjuvant radiochemotherapy significantly alters the phenotype of plasmacytoid dendritic cells and 6-Sulfo LacNAc(+) monocytes in rectal cancer. Front Immunol. 2019;10:602. doi:10.3389/fimmu.2019.00602.
   PubMed Web of Science ®Google Scholar
• Gatti G, Betts C, Rocha D, Nicola M, Grupe V, Ditada C, Nuñez NG, Roselli E, Araya P, Dutto J, et al. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Res. 2021;23(1):40. doi:10.1186/s13058-021-01418-7.
   PubMed Web of Science ®Google Scholar
• Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J Immunother Cancer. 2019;7(1):155. doi:10.1186/s40425-019-0630-0.
   PubMedGoogle Scholar
• van der Sande ME, Figueiredo N, Beets GL Management and outcome of local regrowths in a watch-and-wait prospective cohort for complete responses in rectal cancer. Ann Surg. 2021;274(6):e1056–e62.
   PubMed Web of Science ®Google Scholar